Literature DB >> 18280098

Duplex ultrasound of the superficial femoral artery is a better screening tool than ankle-brachial index to identify at risk patients with lower extremity atherosclerosis.

D Preston Flanigan1, Jeffrey L Ballard, Doreen Robinson, Mark Galliano, Gina Blecker, Timothy R S Harward.   

Abstract

OBJECTIVES: The purpose of vascular disease screening is early identification of atherosclerotic disease and the aim of an ankle-brachial index (ABI) is to identify lower extremity (LE) atherosclerosis as a marker for coronary artery disease (CAD). However, early evidence of atherosclerosis may be present in the superficial femoral artery (SFA) with a normal resting ABI. This study was performed to determine if SFA duplex ultrasound (DUS) could detect more patients with LE atherosclerosis than an ABI; be performed in the same or less time as the ABI measurement; and be associated with similar vascular disease markers as the ABI.
METHODS: From January through November 2006, 585 patients were screened for peripheral arterial disease. SFA DUS was included in this Institutional Review Board approved program and demographic/ultrasound data were collected prospectively. SFA DUS findings were divided into six categories. Plaque w/o color change or worse and ABI <0.90 or >1.20 were considered to be abnormal. Data were evaluated using decision matrix and logistical regression analysis.
RESULTS: Sensitivity and specificity of SFA DUS using the ABI as the benchmark was 100% and 88%, respectively. Sensitivity and specificity of ABI was 17% and 100%, respectively, using DUS as the standard. DUS detected atherosclerotic disease in 143 SFAs (93 patients) in which the ipsilateral ABI was normal, and there were no false negative SFA DUS studies. Multivariate logistic regression analysis demonstrated the following variables to be significantly and independently associated with an abnormal SFA DUS as well as an abnormal ABI: history of claudication, history of myocardial infarction, and an abnormal carotid DUS. Additional variables (current or past smoker and age >55) were also independently associated with an abnormal SFA DUS but not with an abnormal ABI. Mean time to complete bilateral testing was essentially the same for both tests.
CONCLUSIONS: SFA DUS is an accurate screening tool and can be utilized in screening protocols in place of the time-honored ABI without prolonging the examination. Traditional vascular disease markers that are found in patients with an abnormal ABI are also associated with an abnormal SFA DUS. SFA DUS identifies more patients with early LE atherosclerosis than does ABI without missing significant popliteal/tibial artery occlusive disease. Finally, an abnormal SFA DUS can be used as an indirect marker to identify more potentially at risk patients with CAD.

Entities:  

Mesh:

Year:  2008        PMID: 18280098     DOI: 10.1016/j.jvs.2007.11.023

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

1.  Women's Reproductive History and Pre-Clinical Peripheral Arterial Disease in Late Life: The San Diego Population Study.

Authors:  Yamnia I Cortés; Nisha Parikh; Matthew A Allison; Michael H Criqui; Natalie Suder; Emma Barinas-Mitchell; Christina L Wassel
Journal:  J Womens Health (Larchmt)       Date:  2018-12-01       Impact factor: 2.681

2.  Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease.

Authors:  Simon Hsu; Dena E Rifkin; Michael H Criqui; Natalie C Suder; Pranav Garimella; Charles Ginsberg; Antoinette M Marasco; Belinda J McQuaide; Emma J Barinas-Mitchell; Matthew A Allison; Christina L Wassel; Joachim H Ix
Journal:  J Vasc Surg       Date:  2017-12-22       Impact factor: 4.268

Review 3.  Vascular imaging in diabetes.

Authors:  K Levitt; L Vivas; B Courtney; K A Connelly
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

4.  Comparison of different exercise ankle pressure indices in the diagnosis of peripheral artery disease.

Authors:  Aaron W Aday; Scott Kinlay; Marie D Gerhard-Herman
Journal:  Vasc Med       Date:  2018-07-11       Impact factor: 3.239

5.  Doppler ultrasonography of the lower extremity arteries: anatomy and scanning guidelines.

Authors:  Ji Young Hwang
Journal:  Ultrasonography       Date:  2017-01-18

6.  Vector Flow Imaging Compared with Digital Subtraction Angiography for Stenosis Assessment in the Superficial Femoral Artery - A Study of Vector Concentration, Velocity Ratio and Stenosis Degree Percentage.

Authors:  Kristoffer Lindskov Hansen; Peter Møller Hansen; Caroline Ewertsen; Lars Lönn; Jørgen Arendt Jensen; Michael Bachmann Nielsen
Journal:  Ultrasound Int Open       Date:  2019-03-15

7.  Correlation of Serum CysC, IMA, and LP-PLA2 Levels With Type 2 Diabetes Mellitus Patients With Lower Extremity Atherosclerotic Occlusive Disease.

Authors:  Fen Feng; Yong Chen; Gang Wang; Ping Huang; Qiaolin Zhu; Bin Zhou
Journal:  Front Surg       Date:  2022-03-09

8.  Femoral Artery Atherosclerosis Is Associated With Physical Function Across the Spectrum of the Ankle-Brachial Index: The San Diego Population Study.

Authors:  Christina L Wassel; Alicia M Ellis; Natalie C Suder; Emma Barinas-Mitchell; Dena E Rifkin; Nketi I Forbang; Julie O Denenberg; Antoinette M Marasco; Belinda J McQuaide; Nancy S Jenny; Matthew A Allison; Joachim H Ix; Michael H Criqui
Journal:  J Am Heart Assoc       Date:  2017-07-20       Impact factor: 5.501

9.  Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) Characterized with Velocity Ratios using Vector Velocity Ultrasound.

Authors:  Peter Møller Hansen; Kristoffer Lindskov Hansen; Mads Møller Pedersen; Theis Lange; Lars Lönn; Jørgen Arendt Jensen; Michael Bachmann Nielsen
Journal:  Ultrasound Int Open       Date:  2018-09-18

10.  Assessment of carotid artery stenosis and lower limb peripheral ischemia before coronary artery bypass grafting operations: a non-randomized clinical trial.

Authors:  Ihab Ali; Hoda Shokri; Mohammed Abd Al Jawad
Journal:  J Cardiothorac Surg       Date:  2020-09-29       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.